Capricor Therapeutics, Inc. (Nassdaq: CAPR) announced that it intends to expand its CAP-1002 clinical development program in Duchenne muscular dystrophy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE